Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Tonix Pharmaceuticals Holding Corp

Market Cap 181M 156M 144M 135M 253M 17.2B 257M 1.7B 663M 8.37B 679M 665M 28.98B P/E Ratio 2026 *
-1.1x
P/E Ratio 2027 * -1.82x
Enterprise Value 181M 156M 144M 135M 253M 17.2B 257M 1.7B 663M 8.37B 679M 665M 28.98B EV / Sales 2026 *
5.85x
EV / Sales 2027 * 2.24x
Free-Float
99.87%
Yield 2026 *
-
Yield 2027 * -
06-08 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
06-08 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
05-28 Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting CI
05-27 Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody CI
05-26 Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment CI
05-11 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Tonix Pharmaceuticals Holding Corp. Secures Commercial Payer Coverage for TONMYA CI
05-04 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
05-04 TD Cowen Initiates Coverage on Tonix Pharmaceuticals With Buy Rating, $22 Price Target MT
04-29 Tonix Pharmaceuticals Holding Corp. Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of Tnx-4800 CI
03-31 Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease CI
03-26 Tonix Pharmaceuticals Doses First Participant in Potential Migraine Treatment Study MT
03-26 Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 CI

Last Transcript: Tonix Pharmaceuticals Holding Corp

Manager TitleAgeSince
Chief Executive Officer 68 2007-11-15
Director of Finance/CFO 52 2016-01-31
Chief Tech/Sci/R&D Officer 57 2025-02-03
Director TitleAgeSince
Chairman 68 2011-09-30
Director/Board Member 66 2017-09-11
Director/Board Member 81 2018-09-04
Change 5-day change 1-year change 3-year change Capi.($)
-2.41%+0.14%+38.28%+154.20% 1,010B
+1.07%+3.48%+53.32%+49.85% 580B
+1.32%+0.22%+19.18%+64.65% 402B
+0.77%0.00%+21.28%+16.70% 330B
+0.44%+3.48%+25.65%+35.66% 281B
-0.85%-2.86%+22.54%+14.67% 280B
+1.66%+1.20%-44.35%-47.35% 197B
+0.32%+1.61%+20.32%+60.01% 192B
-0.22%-2.76%+14.19%+60.09% 156B
Average +0.23%+0.84%+18.93%+45.39% 380.99B
Weighted average by Cap. -0.23%+1.04%+27.77%+70.54%

Financials

2026 *2027 *
Net sales 30.91M 26.7M 24.6M 23.03M 43.16M 2.94B 43.83M 291M 113M 1.43B 116M 114M 4.95B 80.91M 69.88M 64.4M 60.28M 113M 7.69B 115M 760M 296M 3.74B 304M 297M 12.96B
Net income -176M -152M -140M -131M -246M -16.72B -249M -1.65B -645M -8.14B -660M -646M -28.19B -141M -122M -112M -105M -197M -13.38B -200M -1.32B -516M -6.51B -528M -517M -22.55B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!